Request Demo

Last update 08 May 2025

MFSD6

Last update 08 May 2025

Basic Info

Synonyms

FLJ20160, Macrophage MHC class I receptor 2 homolog, major facilitator superfamily domain containing 6

+ [3]

Introduction-

Drugs associated with MFSD6

MFSD6-Fc(CH3)

Target

MFSD6

Mechanism

MFSD6 modulators

Active Org.

Jilin University

Originator Org.

Jilin University

Active Indication

Poliomyelitis

Inactive Indication-

Drug Highest PhaseDiscovery

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with MFSD6

100 Translational Medicine associated with MFSD6

0 Patents (Medical) associated with MFSD6

Literatures (Medical) associated with MFSD6

27 Mar 2025·Open Forum Infectious Diseases

Patterns of Decline in Measles, Mumps, and Rubella Neutralizing Antibodies and Protection Levels Through 10 Years After a Second and Third Dose of MMR Vaccine

Article

Author: Nguyen, Huong Q ; McClure, David L ; Lutz, Chelsea S ; Crooke, Stephen N ; Masters, Nina B ; Colley, Heather ; Chen, Min-hsin ; Marin, Mona ; Sowers, Sun B

AbstractBackgroundIn the United States, 2 doses of measles-mumps-rubella (MMR)–containing vaccines are recommended routinely during childhood; a third dose may be given under certain circumstances. We present observed seroprotection rates and estimate long-term dynamics of measles, mumps, and rubella neutralizing antibody (nAb) levels among 2- and 3-dose MMR (MMR2 and MMR3, respectively) vaccinees.MethodsPersons who received MMR2 at age 4–12 years or MMR3 at age 18–31 years were enrolled in 1994–1995 and 2009–2010, respectively. Per cohort, sera were collected before vaccination (baseline) and at various intervals ranging from 1 month to 10 years postvaccination to assess nAb levels. Annual changes in nAb levels per virus and cohort were estimated through 10 years postvaccination using generalized estimating equations. Models were stratified by baseline nAb levels.ResultsAmong MMR2 participants (n = 621), 93.7%, 73.4%, and 83.9% had protective nAb levels against measles, mumps, and rubella, respectively, at the 10-year visit; among MMR3 participants (n = 665), 90.5%, 69.1%, and 100% had protective nAb levels, respectively, at the 9–11-year visit. Estimated nAb levels declined annually across both cohorts, all viruses, and baseline nAb strata, though patterns and magnitude varied. More than one-quarter of participants had mumps nAb levels below the presumed seroprotection threshold at the terminal visits.ConclusionsThese findings indicate that even when MMR antibodies wane, protection against disease is largely retained. Waning of mumps antibodies was greater than for measles and rubella in both 2- and 3-dose vaccinees, likely because a greater proportion failed to mount a robust initial response.

01 Feb 2025·Cell Host & Microbe

MFSD6 is an entry receptor for respiratory enterovirus D68

Article

Author: Yang, Jiaxin ; Yu, Xiao-Fang ; Liu, Xize ; Wang, Yonggang ; Huang, Yuehan ; Li, Huili ; Wei, Wei ; Xue, Ling ; Ni, Fushun ; Tang, Yubin ; Yu, Qing ; Li, Zhaoxue ; Wang, Shijin ; Guo, Haoran ; Zhou, Junfeng ; Yu, Zhenglei ; Gao, Delong

Enterovirus D68 (EV-D68) is a leading non-polio enterovirus that causes severe respiratory diseases and poliomyelitis-like illness in children. Viral entry represents a potential multifaceted target for antiviral intervention; however, there are no approved inhibitors to block EV-D68. Here, we identify the functionally undescribed membrane protein major facilitator superfamily-domain-containing protein 6 (MFSD6) as an EV-D68 entry factor amenable to therapeutic intervention. Specifically, MFSD6 expression is crucial for EV-D68 replication. MFSD6 binds to EV-D68 particles and is necessary for virus attachment to cells. The second extracellular domain of the MFSD6 molecule is involved in the recognition of EV-D68. On the basis of these findings, we engineered a recombinant protein complex comprising the MFSD6 ectodomain fused to Fc (MFSD6-Fc(CH3)), which potently inhibited EV-D68 uptake. MFSD6-Fc(CH3) effectively blocked EV-D68 infection in vitro and prevented lethality in newborn mice. In conclusion, our study not only identifies MFSD6 as an EV-D68 entry factor but also reveals a potential antiviral target and therapeutic agent.

01 Jul 2023·European review for medical and pharmacological sciences

A new marker of coronary collateral flow in patients presenting with acute myocardial infarction.

Article

Author: Çelikkol, A ; Çınar, D T ; Alpsoy, Ş ; Donbaloğlu, O ; Aydın, C ; Demirkıran, A ; Böyük, F ; Yılmaz, A ; Topçu, B

OBJECTIVEMultimerin-2 is an adhesion substrate between pericytes and basal membranes during angiogenesis. The present study aimed to assess the relationship between serum Multimerin-2 and coronary collateral flow grade.PATIENTS AND METHODSBetween April 2022 and August 2022, 88 patients with subacute ST-elevation myocardial infarction were included in this study. The main inclusion criteria were patients who present 12-48 hours after symptom onset and aged between 18 and 90 years. The patients were divided into two groups according to the Rentrop classification: poor collateral group (Rentrop grade 0-1) and good collateral group (Rentrop grade 2-3). Biochemical and hematological parameters were measured before coronary angiography.RESULTSSerum Multimerin-2 levels were found to be significantly different between the two groups, and levels were higher in the Rentrop 2-3 group than in the Rentrop 0-1 group (3,527.9 ± 1,194.2 pg/ml and 946.7 ± 249.1 pg/ml; p < 0.00). Receiver operating characteristic curve analysis indicated that the area under the curve was 0.918 (p = 0.001), and the best cut-off value of 849 pg/ml had a sensitivity of 90.1% and a specificity of 84.1% for predicting Rentrop grade 2-3 coronary flow. The number of patients with low left ventricular ejection fraction (LVEF) by echocardiography at 30 days was significantly higher in patients with poor collateralization.CONCLUSIONSMultimerin-2 levels were found to be higher in patients with Rentrop grade 2-3 coronary flow than Rentrop grade 0-1 coronary flow after myocardial infarction. We detected a potential relationship between MMR-2 and good coronary collateral formation.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

MFSD6

Basic Info

Related

Analysis